Full Text View
Tabular View
No Study Results Posted
Related Studies
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (SPERA)
This study is ongoing, but not recruiting participants.
First Received: March 20, 2007   Last Updated: January 8, 2009   History of Changes
Sponsor: GPC Biotech
Information provided by: GPC Biotech
ClinicalTrials.gov Identifier: NCT00450970
  Purpose

The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral satraplatin in this patient population.


Condition Intervention Phase
Prostate Cancer
Drug: Oral Satraplatin
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)

Resource links provided by NLM:


Further study details as provided by GPC Biotech:

Primary Outcome Measures:
  • The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease. [ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]
  • To evaluate the safety of Satraplatin in these patients. [ Time Frame: Weekly blood tests and evaluation by MD prior to each cycle and for thirty days following discontinuation of the therapy. ]

Estimated Enrollment: 1000
Study Start Date: February 2007
Estimated Study Completion Date: December 2007
Intervention Details:
    Drug: Oral Satraplatin
    The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
Detailed Description:

*****UPDATE***** On October 30th, 2007 GPC Biotech announced topline overall survival results for the Phase III trial in hormone refractory prostate cancer-Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial.

The trial evaluated satraplatin plus prednisone versus placebo plus prednisone as a second-line treatment in 950 patients with hormone-refractory prostate cancer (HRPC). The companies reported that the trial did not achieve the endpoint of overall survival (p=0.80, stratified log rank analysis). The median was 61.3 weeks for the satraplatin arm compared to 61.4 weeks for the control group and the hazard ratio was 0.97 (95% CI: 0.83, 1.13). The companies are currently conducting pre-specified subset analyses.

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic(Stage D2)prostate cancer
  • Progression after unlimited prior cytotoxic chemotherapy regimens
  • ECOG Performance status equal/less than 2
  • Surgical or medical castration
  • Adequate bone marrow, liver, and renal function
  • Informed consent
  • Patients treated with bisphosphonates prior to entry are eligible and should continue bisphosphonates therapy while on this trial

Exclusion Criteria:

  • Serious concurrent uncontrolled medical disorder
  • Malignant disease requiring on-going therapy
  • Prior significant RT/radionuclide therapy
  • Major GI surgery or GI disease affecting absorption
  • Disease where corticosteroids are contraindicated
  • Brain metastases
  • Poorly-controlled or uncontrolled insulin-dependent diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00450970

  Hide Study Locations
Locations
United States, Alabama
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
Carraway Cancer Clinic
Birmingham, Alabama, United States, 35234
Birmingham Hematology and Oncology
Birmingham, Alabama, United States, 35235
United States, Alaska
Providence Alaska Medical Center
Anchorage, Alaska, United States, 99508
United States, Arkansas
Clopton Clinic
Jonesboro, Arkansas, United States, 72401
Genesis Cancer Center
Hot Springs, Arkansas, United States, 71913
United States, California
Medical Oncology Care Associates
Orange, California, United States, 92868
Stockton Hematology Oncology Medical Group
Stockton, California, United States, 95204
Santa Barbara Hematology Oncology Medical Group
Santa Barbara, California, United States, 93105
Pacific Hematology Oncology Associates
San Francisco, California, United States, 94115
North Valley Hematology/Oncology Medical Group
Mission Hills, California, United States, 91345
Sharp Clinical Oncology Research
San Diego, California, United States, 92123
Desert Cancer Center
Rancho Mirage, California, United States, 92270
Sierra Nevada Oncology
Truckee, California, United States, 96161
Pacific Cancer Medical Center, Inc
Anaheim, California, United States, 92801
Newport Cancer Care Medical Assoc., Inc.
Newport Beach, California, United States, 92663
Michael Harris MD
Mission Viejo, California, United States, 92691
Pacific Shores Medical Group
Long Beach, California, United States, 90813
East Valley Hematology Oncology Medical Group
Burbank, California, United States, 91505
Santa Barbara Hemotology
Santa Barbara, California, United States, 93105
United States, Colorado
Rocky Mountain Cancer Center
Colorado Springs, Colorado, United States, 80909
United States, Connecticut
Hematology Oncology
Stamford, Connecticut, United States, 06902
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States, 06360
Oncology Associates of Bridgeport
Bridgeport, Connecticut, United States, 06611
Davis, Posteraro, and Wasser, MDs, LLP
Manchester, Connecticut, United States, 06040
Medical Specialists of Fairfield, LLC
Fairfield, Connecticut, United States, 06284
Whittigham Cancer Center at Norwalk Hospital
Norwalk, Connecticut, United States, 06856
Connecticut Oncology & Hematology, LLP
Torrington, Connecticut, United States, 06790
United States, Florida
Marc I. Saltzman
Miami, Florida, United States, 33138
Florida Cancer Care Specialists-Fort Myers Summerlin Office
Fort Myers, Florida, United States, 33908
ICON
Jacksonville, Florida, United States, 32256
Gainesville Hematology Oncology Associates
Gainesville, Florida, United States, 32605
Lakeland Regional Medical Center
Lakeland, Florida, United States, 33805
Sacred Heart Hospital Cancer Research
Pensacola, Florida, United States, 32504
Florida Cancer Specalists
Bradenton, Florida, United States, 34209
Center for Hematology-Oncology
Boca Raton, Florida, United States, 33486
Mid-Florida Hematology & Oncology Centers
Orange City, Florida, United States, 32763
Ocala Oncology Center
Ocala, Florida, United States, 34474
Florida Cancer Specialists
Port Charlotte, Florida, United States, 33980
Florida Cancer Specialists
Port Charlotte, Florida, United States, 33980
MIMA Century Research Assoc.
Melbourne, Florida, United States, 32901
United States, Georgia
GA Urology
Decatur, Georgia, United States, 30033
Suburban Hematology-Oncology Assoc., PC
Lawrenceville, Georgia, United States, 30045
Notheast Georgia Cancer Care, LLC
Athens, Georgia, United States, 30607
Medical Oncology Assoc. of Augusta, PC
Augusta, Georgia, United States, 30901
United States, Illinois
Urology Associates, S.C.
Mattoon, Illinois, United States, 61938
Mid-Illinois Hematology and Oncology Assoc., LTD
Normal, Illinois, United States, 61761
University of Chicago
Chicago, Illinois, United States, 60637
Medical & Surgical Spealists, LLC
Galesburg, Illinois, United States, 61401
Oncology Hematology Associates of Central IL, PC
Peoria, Illinois, United States, 61615
United States, Indiana
Fort Wayne Medical Oncology Hematology, Inc.
Fort Wayne, Indiana, United States, 46815
Mahendra M. Shah, MD, FACP
Hammond, Indiana, United States, 46320
United States, Iowa
Heartland Oncology & Hematology, LLP
Council Bluffs, Iowa, United States, 51503
Cedar Valley Medical Specialists
Waterloo, Iowa, United States, 50702
Iowa Blood and Cancer Care, PLC
Cedar Rapids, Iowa, United States, 52402
McFarland Clinic PC
Ames, Iowa, United States, 50010
United States, Kentucky
Drs.Caroll, Sheth and Raghavan
Louisville, Kentucky, United States, 40215
United States, Louisiana
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States, 70809
United States, Maryland
The Center for Clinical Research
Hagerstown, Maryland, United States, 21740
Associates in Oncology/Hematology
Rockville, Maryland, United States, 20850
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
United States, Massachusetts
Lahey Clinic
Burlington, Massachusetts, United States, 01805
United States, Michigan
Kalamazoo Hematology and Oncology
Kalamazoo, Michigan, United States, 49048
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States, 49546
United States, Mississippi
NW MS Hem/Onc (Tupelo)
Tupelo, Mississippi, United States, 38801
Jackson Oncology Associates
Jackson, Mississippi, United States, 39202
United States, Missouri
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65203
Columbia Comprehensive Cancer Care Center
Columbia, Missouri, United States, 65201
The Center for Cancer Care & Research
St. Louis, Missouri, United States, 63141
St. Johns Mercy Medical Center
St. Louis, Missouri, United States, 63141
United States, Montana
The Billings Clinic
Billings, Montana, United States, 59101
United States, Nebraska
Nebraska Hematology-Oncology,PC
Lincoln, Nebraska, United States, 68506
Saint Francis Memoiral Hospital
Grand Island, Nebraska, United States, 68803
United States, New Jersey
Cancer Care at St. Claire's
Denville, New Jersey, United States, 07834
Northern Valley Medical
Westwood, New Jersey, United States, 07675
Hematology Oncology Associates of Northern New Jersey
Morristown, New Jersey, United States, 07960
United States, New York
Richmond University Medical Center
Staten Island, New York, United States, 10310
North Shore Hematology Oncology Assoc.
E. Setauket, New York, United States, 11733
Hematology Oncology Assoc. of W. Suffolk, PC
Bay Shore, New York, United States, 11706
The Mary Imogene Bassett Hospital
Cooperstown, New York, United States, 13326
United States, North Carolina
Gaston Hematology and Oncology
Gastonia, North Carolina, United States, 28054
Cancer Center of North Carolina
Raleigh, North Carolina, United States, 27614
United States, North Dakota
MeritCare Clinical Research
Fargo, North Dakota, United States, 58122
Trinity Cancer Care Center
Minot, North Dakota, United States, 58701
United States, Ohio
Tricounty Hem/Onc Associates
Canton, Ohio, United States, 44718
Hematology-Oncology Consultants, Inc
Columbus, Ohio, United States, 43235
Ohio Cancer Specialists
Mansfield, Ohio, United States, 44907
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Mid-Ohio Oncology/Hematology
Columbus, Ohio, United States, 43219
United States, Oklahoma
Cancer Care Associates
Tulsa, Oklahoma, United States, 73146
Cancer Care Associates
Oklahoma City, Oklahoma, United States, 73112
Cancer Specialists of Oklahoma
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Greater Philadelphia Cancer Center
Philadelphia, Pennsylvania, United States, 19114
Lancaster Cancer Center, Ltd.
Lancaster, Pennsylvania, United States, 17601
Ephrata Cancer Center
Ephrata, Pennsylvania, United States, 17522
United States, South Carolina
Carolina Health Care
Florence, South Carolina, United States, 29501
United States, Tennessee
Kingsport Hematology Oncology
Kingsport, Tennessee, United States, 37660
The Jones Clinic
Germantown, Tennessee, United States, 38138
McLeod Cancer and Blood Center
Johnson City, Tennessee, United States, 37604
Mid-South Cancer Center
Germantown, Tennessee, United States, 38138
Mid-South Cancer Center, PC
Germantown, Tennessee, United States, 38138
Boston Baskin Cancer Group D/B/A/ UTCI
Memphis, Tennessee, United States, 38104
United States, Texas
Center for Oncology Research and Treatment
Dallas, Texas, United States, 75230
Lone Star Oncology Consultants
Austin, Texas, United States, 78759
Coastal Bend Cancer Center
Corpus Christi, Texas, United States, 78463
Texas Oncology Cancer Center, PA
Austin, Texas, United States, 78731
Harrington Cancer Center
Amarillo, Texas, United States, 79106
Cancer Care Centers of South Texas
New Braunfels, Texas, United States, 78130
Texas Oncology
Dallas, Texas, United States, 75231
Dallas Oncology Consultants, PA
Dallas, Texas, United States, 75237
Texas Cancer Center
Denton, Texas, United States, 76210
Cancer Care Centers of South Texas
Fredericksburg, Texas, United States, 78624
Clinical Oncology & Hematology, LLP
Dallas, Texas, United States, 75235
Allison Cancer Center
Midland, Texas, United States, 79701
Mitchell Medical Clinic
Daingerfield, Texas, United States, 75638
United States, Utah
Northern Utah Associates
Ogden, Utah, United States, 84403
United States, Virginia
Virginia Oncology Associates
Newport News, Virginia, United States, 23606
Peninsula Cancer Institute
Newport News, Virginia, United States, 23601
United States, Washington
Northwest Cancer Specialists, PC
Vancouver, Washington, United States, 98684
Sacred Heart Medical Center - Providence Cancer Care Center
Spokane, Washington, United States, 99204
United States, Wisconsin
Green Bay Oncology, Ltd.
Green Bay, Wisconsin, United States, 54301
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
GPC Biotech
Investigators
Study Director: Philippe Pultar, MD GPC Biotech Inc.
  More Information

No publications provided

Study ID Numbers: SAT3-06-04
Study First Received: March 20, 2007
Last Updated: January 8, 2009
ClinicalTrials.gov Identifier: NCT00450970     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by GPC Biotech:
Hormone Refractory Prostate Cancer (HRPC)
Hormone Refractory Prostate Cancer
Unlimited Prior Cytotoxic Chemotherapy Regimens

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Prednisone
Satraplatin
Antineoplastic Agents, Hormonal
Genital Neoplasms, Male
Prostatic Diseases
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Urogenital Neoplasms
Genital Diseases, Male
Glucocorticoids
Hormones
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Therapeutic Uses
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 27, 2009